Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IP-001 is a novel, non-cytotoxic, immunostimulatory glycan polymer administered as a single intratumoral injection into the ablation zone immediately following standard of care image-guided microwave thermal ablation of a target tumor lesion.”In the company’s words, NCT07321847 on ClinicalTrials.gov
- Tested for
- Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases, Colorectal Liver Metastasis (CRLM), Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer and 1 more
- Main trialPhase 2/3
- “The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal cancer that has spread only to the liver. The study will determine if injecting IP-001 into a liver tumor(s) after ablation will reduce the risk of cancer coming back in the liver and from spreading elsewhere in the body, will stimulate the immune system, will have any side effects, and will help improve a patient's response to other cancer therapies. Researchers will…”In the company’s words, NCT07321847 on ClinicalTrials.gov
Other drugs for Colorectal Cancer (CRC)
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- Dec 2033Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | Dec 2033 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases | |
| Phase 1/2Active, not recruiting | Feb 2025 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026